CTC-DNA + ctDNA Assay
Early Cancer Detection (e.g., Lung Cancer)
Clinical StudiesActive
Key Facts
Indication
Early Cancer Detection (e.g., Lung Cancer)
Phase
Clinical Studies
Status
Active
Company
About Rarecells
Rarecells is a private, commercial-stage diagnostics company pioneering a next-generation liquid biopsy platform for the ultra-early detection of cancer. Its CE-IVD-certified ISET® technology isolates circulating tumor cells (CTCs) from blood with unparalleled sensitivity, capable of detecting a single tumor cell, and is being commercialized for cancer testing in Paris. The company's R&D strategy combines CTC-DNA analysis with circulating tumor DNA (ctDNA) and AI-driven multiomics to significantly enhance detection sensitivity and genomic insight, aiming to set a new global standard in precision oncology and early intervention.
View full company profile